Thyroid Cancer (Oncology) Drug Pipeline Landscape Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Thyroid Cancer (Oncology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
Thyroid Cancer - Drugs In Development, 2021, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.
The publisher's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 53, 36, 5, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 2 molecules, respectively.
Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Thyroid Cancer - Overview
- Thyroid Cancer - Therapeutics Development
- Thyroid Cancer - Therapeutics Assessment
- Thyroid Cancer - Companies Involved in Therapeutics Development
- Thyroid Cancer - Drug Profiles
- Thyroid Cancer - Dormant Projects
- Thyroid Cancer - Discontinued Products
- Thyroid Cancer - Product Development Milestones
- ABM Therapeutics Inc
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- AffyImmune Therapeutics Inc
- Akeso Inc
- Alphamab Oncology
- Arch Oncology Inc
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- Bayer AG
- BeiGene Ltd
- Beijing Konruns Pharmaceutical Co Ltd
- Bicara Therapeutics Inc
- BioMed Valley Discoveries Inc
- Biovista Inc
- Blueprint Medicines Corp
- BNOAT Oncology Inc
- Boehringer Ingelheim International GmbH among others
For more information about this report visit https://www.researchandmarkets.com/r/fnfe2b
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900